IRF9 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control provided. Knockout achieved by CRISPR/Cas9; X = 1 bp insertion after Met102 of the WT protein
Frameshift = 98%.
Images
Key facts
- Cell type
- MCF7
- Species or organism
- Human
- Tissue
- Breast
- Form
- Liquid
- Knockout validation
- Next Generation Sequencing
- Mutation description
- Knockout achieved by CRISPR/Cas9; X = 1 bp insertion after Met102 of the WT protein Frameshift = 98%
Alternative names
IFN-alpha-responsive transcription factor subunit, IRF9_HUMAN, ISGF-3, ISGF-3 gamma, ISGF3 p48 subunit, ISGF3G, Interferon regulatory factor 9, Interferon-stimulated gene factor 3 gamma, OTTHUMP00000164692, OTTHUMP00000164693, P48, Transcriptional regulator ISGF3 subunit gamma, interferon stimulated transcription factor 3, interferon-stimulated transcription factor 3, gamma 48kDa
Recommended products
IRF9 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control provided. Knockout achieved by CRISPR/Cas9; X = 1 bp insertion after Met102 of the WT protein
Frameshift = 98%.
Key facts
- Cell type
- MCF7
- Species or organism
- Human
- Tissue
- Breast
- Form
- Liquid
- Knockout validation
- Next Generation Sequencing
- Mutation description
- Knockout achieved by CRISPR/Cas9; X = 1 bp insertion after Met102 of the WT protein Frameshift = 98%
- Disease
- Adenocarcinoma
- Concentration
Properties
- Gene name
- IRF9
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Next Generation Sequencing
- Zygosity
- Homozygous
Cell culture
- Biosafety level
- EU: 1 US: 1
- Adherent/suspension
- Adherent
- Gender
- Female
Handling procedures
- Initial handling guidelines
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.- Subculture guidelines
- Slow to trypsinise.
- All seeding densities should be based on cell counts gained by established methods.
- A guide seeding density of 5-7x104 cells/cm2 is recommended.
- Cells should be passaged when they have achieved 80-90% confluence.
- Culture medium
- MEM + 10% FBS + 0.01 mg/ml bovine insulin
- Cryopreservation medium
- Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Storage
- Shipped at conditions
- Dry Ice
- Appropriate short-term storage duration
- 1-2 weeks
- Appropriate short-term storage conditions
- -196°C
- Appropriate long-term storage conditions
- -196°C
Notes
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
Interferon regulatory factor 9 (IRF-9) also known as ISGF3-γ is a critical component in the transcriptional regulation of interferon-stimulated genes. This protein with a mass of approximately 48 kDa serves as an important mediator in the interferon signaling pathway. IRF-9 is widely expressed in various tissues where it functions as part of the immune response to pathogens. Its expression can be induced by interferons signaling molecules involved in antiviral defense.
- Biological function summary
IRF-9 participates in the assembly of the transcription factor complex ISGF3 alongside STAT1 and STAT2. This complex translocates into the nucleus to initiate the transcription of interferon-stimulated genes that promote antiviral states. IRF-9 through this functional role impacts a range of cellular responses including proliferation apoptosis and immune regulation. It affects the temporal and spatial aspects of gene expression in response to interferons.
- Pathways
IRF-9 plays a significant role in both the Jak-STAT and interferon signaling pathways. These pathways are essential for the activation of genes involved in immune defense. Through its involvement in these pathways IRF-9 interacts with proteins such as STAT1 and STAT2 creating a bridge between extracellular signals and gene activation. This involvement ensures that cells can respond effectively to viral infections enhancing innate and adaptive immune responses.
- Associated diseases and disorders
IRF-9 has been implicated in autoimmune diseases and certain cancers. Dysfunction in the IRF-9 associated pathways can lead to conditions such as systemic lupus erythematosus where inefficient regulation of immune responses occurs. In cancer altered IRF-9 expression can contribute to uncontrolled cell proliferation. These connections highlight the importance of IRF-9 in maintaining cellular homeostasis and immune integrity. IRF-9's interaction with STAT proteins and interferon pathways highlights its central role in these disease processes.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
1 product image
Next Generation Sequencing - Human IRF9 (Interferon regulatory factor 9) knockout MCF7 cell line (ab274943)
1 bp insertion after Met102 of the WT protein
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com